- Home
- UPXI vs THAR Comparison
UPXI vs THAR Comparison
Compare UPXI & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | THAR |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.0M | 83.1M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | UPXI | THAR |
|---|---|---|
| Price | $2.31 | $2.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 4.4M | 287.6K |
| Earning Date | 11-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $20,694,575.00 | N/A |
| Revenue This Year | $145.75 | N/A |
| Revenue Next Year | $12.88 | N/A |
| P/E Ratio | $1.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.90 | $0.95 |
| 52 Week High | $22.57 | $9.08 |
Technical Indicators
Market Signals| Indicator | UPXI | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 31.55 | 41.25 |
| Support Level | $2.29 | $2.36 |
| Resistance Level | $3.00 | $2.75 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 5.37 | 8.51 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.